Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders.
In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a debilitating rare disease affecting children and young adults.
The company’s development program is using an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals.
Dynacure’s leadership team includes Stephane van Rooijen (CEO), Frédéric Legros (COO) and Leen Thielemans (Head of Development).
The team will focus on the company’s preclinical and clinical development programs in CNM and the expansion of its pipeline in rare disease treatments.
Stephane van Rooijen, Chief Executive Officer
Stephane has an extensive experience in the life sciences orphan biotech industry, previously working at Genzyme, Viropharma-Shire and Confo Therapeutics.
He has a medical degree from the University of Leuven in Belgium and obtained an MBA at the Erasmus University Rotterdam and Georgetown University of Washington DC.
Frédéric Legros, Chief Operating Officer
Frédéric has over a decade of experience in business development and strategic management. Before joining Dynacure, Frédéric was Vice President and Corporate Head of Business Development at Valneva SE.
Frédéric obtained his PhD in molecular biology in 2002 at the Institute of Myology in Paris. He also holds a business degree from NEOMA business school, France.
Leen Thielemans, Head of Development
Leen brings with her over fifteen years of experience in pharmaceutical R and D, from drug discovery to early clinical development. Leen previously worked at Johnson amd Johnson, 4AZA-Elbion, Movetis and Shire.
Leen Thielemans is a bio-engineer from the University of Leuven and an epidemiologist with a PhD in medical sciences.
